BioLineRx (NASDAQ:BLRX) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a report on Monday, November 25th.

BioLineRx Stock Performance

Shares of BLRX stock opened at $0.23 on Thursday. BioLineRx has a 52-week low of $0.19 and a 52-week high of $1.64. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The stock has a market cap of $18.66 million, a PE ratio of -1.06 and a beta of 1.39. The business has a 50-day simple moving average of $0.35 and a 200-day simple moving average of $0.54.

Institutional Trading of BioLineRx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CVI Holdings LLC purchased a new stake in shares of BioLineRx during the 2nd quarter worth about $462,000. PVG Asset Management Corp acquired a new position in BioLineRx in the 2nd quarter worth about $70,000. Finally, Atria Investments Inc raised its holdings in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the period. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.